A Risk Assessment of the Jaffe vs Enzymatic Method for Creatinine Measurement in an Outpatient Population

被引:55
作者
Schmidt, Robert L. [1 ,2 ]
Straseski, Joely A. [1 ,2 ]
Raphael, Kalani L. [3 ]
Adams, Austin H. [1 ,2 ]
Lehman, Christopher M. [1 ,2 ]
机构
[1] Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84132 USA
[2] Univ Utah, Hlth Sci Ctr, ARUP Labs, Salt Lake City, UT USA
[3] Univ Utah, Hlth Sci Ctr, Dept Internal Med, Div Nephrol, Salt Lake City, UT USA
关键词
KIDNEY-DISEASE; RENAL-DISEASE; EQUATION; TIME;
D O I
10.1371/journal.pone.0143205
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background The Jaffe and enzymatic methods are the two most common methods for measuring serum creatinine. The Jaffe method is less expensive than the enzymatic method but is also more susceptible to interferences. Interferences can lead to misdiagnosis but interferences may vary by patient population. The overall risk associated with the Jaffe method depends on the probability of misclassification and the consequences of misclassification. This study assessed the risk associated with the Jaffe method in an outpatient population. We analyzed the discordance rate in the estimated glomerular filtration rate based on serum creatinine measurements obtained by the Jaffe and enzymatic method. Methods Method comparison and risk analysis. Five hundred twenty-nine eGFRs obtained by the Jaffe and enzymatic method were compared at four clinical decision limits. We determined the probability of discordance and the consequence of misclassification at each decision limit to evaluate the overall risk. Results We obtained 529 paired observations. Of these, 29 (5.5%) were discordant with respect to one of the decision limits (i.e. 15, 30, 45 or 60 ml/min/1.73m(2)). The magnitude of the differences (Jaffe result minus enzymatic result) were significant relative to analytical variation in 21 of the 29 (72%) of the discordant results. The magnitude of the differences were not significant relative to biological variation. The risk associated with misclassification was greatest at the 60 ml/min/1.73m(2) decision limit because the probability of misclassification and the potential for adverse outcomes were greatest at that decision limit. Conclusion The Jaffe method is subject to bias due to interfering substances ( loss of analytical specificity). The risk of misclassification is greatest at the 60 ml/min/1.73m(2) decision limit; however, the risk of misclassification due to bias is much less than the risk of misclassification due to biological variation. The Jaffe method may pose low risk in selected populations if eGFR results near the 60 ml/min/1.73m(2) decision limit are interpreted with caution.
引用
收藏
页数:21
相关论文
共 27 条
[1]  
[Anonymous], 2001, Biological variation: from principles to practice
[2]   The uncertainty of the eGFR [J].
Badrick T. ;
Turner P. .
Indian Journal of Clinical Biochemistry, 2013, 28 (3) :242-247
[3]   Prime Time for Enzymatic Creatinine Methods in Pediatrics [J].
Cobbaert, Christa M. ;
Baadenhuijsen, Henk ;
Weykamp, Cas W. .
CLINICAL CHEMISTRY, 2009, 55 (03) :549-558
[4]  
College of American Pathologists, 2014, CHEM THER MON PART S
[5]   Clinical evaluation of analytical variations in serum creatinine measurements: why laboratories should abandon Jaffe techniques [J].
Drion, Iefke ;
Cobbaert, Christa ;
Groenier, Klaas H. ;
Weykamp, Cas ;
Bilo, Henk J. G. ;
Wetzels, Jack F. M. ;
Kleefstra, Nanne .
BMC NEPHROLOGY, 2012, 13
[6]   K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification - Foreword [J].
Eknoyan, G ;
Levin, NW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (02) :S14-S266
[7]   Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [J].
Go, AS ;
Chertow, GM ;
Fan, DJ ;
McCulloch, CE ;
Hsu, CY .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (13) :1296-1305
[8]   Specificity Characteristics of 7 Commercial Creatinine Measurement Procedures by Enzymatic and Jaffe Method Principles [J].
Greenberg, Neil ;
Roberts, William L. ;
Bachmann, Lorin M. ;
Wright, Elizabeth C. ;
Dalton, R. Neil ;
Zakowski, Jack J. ;
Miller, W. Greg .
CLINICAL CHEMISTRY, 2012, 58 (02) :391-401
[9]   From biomarkers to medical tests: The changing landscape of test evaluation [J].
Horvath, Andrea R. ;
Lord, Sarah J. ;
StJohn, Andrew ;
Sandberg, Sverre ;
Cobbaert, Christa M. ;
Lorenz, Stefan ;
Monaghan, Phillip J. ;
Verhagen-Kamerbeek, Wilma D. J. ;
Ebert, Christoph ;
Bossuyt, Patrick M. M. .
CLINICA CHIMICA ACTA, 2014, 427 :49-57
[10]   KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD [J].
Inker, Lesley A. ;
Astor, Brad C. ;
Fox, Chester H. ;
Isakova, Tamara ;
Lash, James P. ;
Peralta, Carmen A. ;
Tamura, Manjula Kurella ;
Feldman, Harold I. ;
Rocco, Michael V. ;
Berns, Jeffrey S. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 63 (05) :713-735